IL6 and cancer: Given its central role in cancer biology, targeting the IL-6/GP130 pathway has emerged as a promising therapeutic strategy for cancer treatment, with ongoing research focusing on developing novel inhibitors to effectively disrupt aberrant signaling and improve patient outcomes.